EU Regulator Moves Against Amgen’s Rare-Disease Drug Tavneos

The European Medicines Agency has recommended revoking the EU marketing authorisation for Tavneos, Amgen’s rare disease medicine used in adults with severe, active ANCA associated vasculitis, including granulomatosis with polyangiitis and microscopic polyangiitis. The recommendation is not yet the final legal decision, which sits with the European Commission, but if confirmed, Tavneos would no longer be authorised across the EU.

At the centre of the decision is not only safety, but trust in the evidence base itself. Tavneos was originally supported by the ADVOCATE study, a 331 patient trial comparing a 52 week Tavneos regimen with placebo plus a 20 week course of corticosteroids, alongside standard treatment. At approval, regulators concluded the drug was at least as effective as high dose corticosteroids in inducing remission and offered better longer term remission outcomes.

That conclusion has now been thrown into question. Following a review of new information about how the trial data were handled, EMA’s human medicines committee concluded that the study had breached good clinical practice principles. The agency said the data submitted during the original approval process were incorrect and misleading, and could no longer be relied upon to demonstrate the drug’s effectiveness. Supportive post marketing data and post hoc analyses were also deemed insufficient to prove the medicine’s benefits.

The decision comes amid parallel scrutiny in the US. The FDA has also proposed withdrawing Tavneos, stating that it can no longer conclude there has ever been a valid demonstration of effectiveness for the approved use. The US regulator has also raised concerns about serious post marketing cases of drug induced liver injury, including vanishing bile duct syndrome, a rare but severe form of bile duct damage.

For clinicians, the immediate implications are practical. EMA has recommended that no new patients should start Tavneos, while existing patients should be switched to suitable alternatives. The agency also advised close liver function monitoring until treatment is permanently stopped, especially given the reported risks of drug induced liver injury and vanishing bile duct syndrome, including fatal outcomes.

Amgen has said it remains concerned about the impact on patients and continues to believe Tavneos is an important option for people living with ANCA associated vasculitis. Its European partner, CSL Vifor, is leading discussions with EMA on next steps for patients and healthcare providers.

This case raises a wider issue beyond one product. Rare disease medicine often depends on smaller trials, complex endpoints, and urgent unmet need. Regulators, clinicians, and patients may accept greater uncertainty when options are limited. But this episode shows that uncertainty is not the same as unreliable evidence. When the integrity of pivotal data is questioned, even post marketing experience may not be enough to rescue confidence in a treatment.

For physicians treating rare autoimmune disease, the question is now both clinical and ethical: when access to a valued therapy conflicts with doubts over the evidence behind it, where should the line be drawn?

G-Med excels in HCP marketing by blending digital innovation with data-driven insights, creating an effective platform for reaching healthcare professionals, offering various advertising solutions. By using G-Med to engage HCPs, share data reports, and explore innovative channels, marketers can deliver targeted, impactful messages that foster strong connections. G-Med’s approach ensures that each campaign is tailored, scientifically rigorous, and effective, aligning perfectly with the best practices for successful HCP marketing.   

Contact us today to learn more: Contact@g-med.com